FebriDx gains commercial ground across priority U.S. urgent care accounts
Lumos Diagnostics has reported material commercial progress for its FebriDx point-of-care test across its priority top 100 U.S. urgent care target list, with one top 100 group committing to a network rollout and three tier 1 accounts advancing through validation.
The update, released on 21 July 2026, builds on the company’s 11 June 2026 investor presentation and provides account-level detail on how its U.S. commercialisation strategy is maturing.
Lumos continues to prioritise the top 100 urgent care groups, which the company estimates represent approximately 40% of total U.S. urgent care sites. Combined, the four new accounts detailed in the update represent more than 430 potential sites and correspond to a minimum internally estimated 2.6 million acute respiratory infection (ARI) presentations annually, illustrating the scale of the potential addressable clinical opportunity as these engagements mature.
When big ASX news breaks, our subscribers know first
The four-stage commercial framework driving account progression
To help investors track and communicate how priority accounts advance from initial engagement through to scaled, protocol-driven use of FebriDx, Lumos is now applying a four-stage commercial framework.
-
Qualified opportunities — priority accounts identified and engaged based on patient volume, payer mix, strategic fit and network scale.
-
Clinical and economic validation — targeted clinical performance, reimbursement, workflow and health-economic assessment activities conducted across one or more locations.
-
Network rollout — deployment across multiple sites within an account following successful validation of clinical utility, operational fit and reimbursement readiness.
-
Standardised adoption — FebriDx becomes embedded in standing orders, triage protocols or routine clinical pathways, supporting repeat ordering across the account.
The framework aligns to the pathway demonstrated with existing customer WellStreet Urgent Care. Following a successful initial pilot, the programme expanded to 44 sites and established a pathway for nationwide deployment across WellStreet’s network of more than 165 sites.
The WellStreet expansion to 43 sites across three U.S. regions, with a standing order protocol embedding FebriDx into routine triage for every patient presenting with acute respiratory symptoms, established the commercial template now being replicated across the top 100 target list.
Top 100 group commits to a 30+ site rollout
A leading regional top 100 U.S. urgent care group, owned and operated by a major U.S. health system, has agreed to deploy FebriDx across its entire urgent care network of more than 30 sites. The company internally estimates this represents an opportunity of approximately 200,000 ARI presentations per year.
Internal analysis indicates that approximately 58 of the top 100 urgent care groups are owned by or affiliated with large health systems, highlighting the strategic importance of this channel for Lumos.
The specific health system operates more than 200 sites across a major U.S. metropolitan region, including urgent care centres, hospitals, ambulatory clinics and medical group practices. FebriDx is expected to support ARI triage protocols, antibiotic stewardship initiatives and standardised workflows, with the potential over time to advance toward standardised adoption across the broader network.
Doug Ward, CEO, Lumos Diagnostics
“The expedited pace at which this regional urgent care group moved from discussions through to adoption was an encouraging sign of growing clinical confidence in the FebriDx test.”
Three tier 1 accounts advancing through validation
Three additional urgent care groups are currently progressing through clinical and economic validation across multiple sites, offering a meaningful opportunity for future network deployment.
-
A top 10, a top 25 and a top 30 organisation.
-
Collectively representing more than 230 urgent care sites.
-
Currently progressing through clinical and economic validation across multiple locations.
Doug Ward, CEO, Lumos Diagnostics
“These engagements are consistent with Lumos’ commercialisation approach of focusing resources on large multi-site groups where a successful initial validation can lead to a faster expansion outcome within an existing account. Combined with the U.S. regional health system operator, these four new accounts represent more than 430 potential sites and correspond to a minimum internal estimated 2.6 million ARI presentations annually, illustrating the scale of the potential addressable clinical opportunity as these engagements mature.”
| Account | Ranking | Sites | Current Stage | Est. ARI Opportunity |
|---|---|---|---|---|
| Regional health system group | Top 100 | 30+ | Network rollout | ~200,000/yr |
| Tier 1 group A | Top 10 | Part of 230+ combined | Validation | Not individually disclosed |
| Tier 1 group B | Top 25 | Part of 230+ combined | Validation | Not individually disclosed |
| Tier 1 group C | Top 30 | Part of 230+ combined | Validation | Not individually disclosed |
Why FebriDx matters — the educational angle
FebriDx is a rapid point-of-care test targeting infectious and inflammatory diseases, supporting ARI triage protocols, antibiotic stewardship initiatives and standardised workflows at the point of care.
This capability supports two priorities in high-volume urgent care settings. It aids antibiotic stewardship and it enables faster triage.
For investors, the significance lies in the channel structure. Multi-site urgent care groups are high-volume, repeat-ordering customers, meaning a single account validation can cascade into network-wide adoption and drive recurring demand over time.
Reimbursement rates above the Medicare benchmark of US$41.38 per test, with more than 90% of submitted FebriDx claims being paid, provide the payor-confidence data that large multi-site groups typically require before committing to network-wide standing order protocols.
The investment case and what comes next
The update illustrates how Lumos is converting its targeted top 100 strategy into tangible rollouts, supported by a demonstrated expansion pathway through the WellStreet precedent.
The company will continue to report progress in a manner consistent with the market framework outlined on 11 June 2026, including site growth, geographic expansion and the use of influenza testing as a benchmark for ARI-related commercial opportunity. Lumos also expects to refine how it communicates account maturity using the four-stage progression framework, allowing investors to better assess how individual priority accounts are evolving.
All FebriDx sales in the U.S. are made through Lumos’ exclusive distribution agreement with Phase Scientific, as disclosed to the ASX on 16 July 2025, and Lumos recognises FebriDx revenue when product is shipped from Lumos to Phase Scientific.
Investors should note that the figures disclosed in this update reflect opportunity and pipeline estimates rather than confirmed sales. No booked revenue figures or financial results were disclosed. As set out in the company’s forward-looking statement disclaimer, these estimates are not guarantees of future performance and involve known and unknown risks and uncertainties.
Don’t Miss the Next ASX Healthcare Breakout
Big News Blast, powered by StockWire X, delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button to start receiving real-time alerts the moment ASX healthcare announcements drop.